Gavreto® (pralsetinib)
for Thyroid Cancer

Gavreto (pralsetinib) is an oral targeted therapy used to treat cancers driven by abnormal RET genes, including metastatic non-small cell lung cancer (NSCLC) in adults and advanced thyroid cancer in adults and children 12 and older who need systemic therapy after radioactive iodine has failed. Gavreto blocks the RET protein, which plays a key role in cancer growth, making it effective against RET mutations or fusions.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Thyroid Cancer